2024-01-17 13:00:00
Stéphane Piat doesn’t beat around the bush. The general director of Carmat compares his company to “SpaceX artificial heart“. When the adventure started in 2008, there were five European and American projects. Three have gone bankrupt, and the other two have still not progressed to the clinical development stage in humans. “We are marketedhe congratulates. In 15 years, we have taken 8 or 9 years ahead of the others and in terms of technology, we are much better», assures Stéphane Piat.
But the context is pressing. In Europe and the United States alone, 64 million patients suffer from heart failure, 200,000 of whom end up in terminal heart failure each year. Constantly increasing figures: this pathology is becoming the leading cause of death in the world. At the same time, the number of heart transplants is limited to 6,000 per year. This leaves a gigantic market for artificial hearts, which Carmat estimates to have a value of more than 40 billion dollars (more than 36 billion euros) by 2030.
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Already subscribed? Log in
I will tell you
source
Selected for you
1705527338
#Carmat #SpaceX #artificial #heart #search #financing